Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein

Mult Scler. 2012 Apr;18(4):398-408. doi: 10.1177/1352458512440060. Epub 2012 Feb 16.

Abstract

Background: The pathology of neuromyelitis optica (NMO), in contrast to multiple sclerosis, comprises granulocyte infiltrates along extensive lengths of spinal cord, as well as optic nerve. Furthermore, IFN-β treatment worsens NMO. We recently found that experimental autoimmune encephalomyelitis (EAE) induced with Th17 cells is exacerbated by IFN-β, in contrast to disease induced with Th1 where treatment attenuated symptoms.

Objective: This study demonstrates the similarities between NMO and Th17 EAE and how neutrophils mediate pathology in Th17 disease.

Methods: Levels of blood biomarkers in NMO were assessed by Luminex and ELISA. Effects of IFN-β on neutrophils were assessed by culture assays and immunofluorescence. EAE was induced by transfer of myelin-specific Th1 or Th17 cells and treated with Sivelestat sodium hydrate, a neutrophil elastase inhibitor.

Results: We show Th17 cytokines, granulocyte chemokines, type 1 interferon and neutrophil elastase are elevated in patients with definitive NMO. In culture, we find that IFN-β stimulates neutrophils to release neutrophil elastase. In Th17 EAE, we demonstrate neutrophilic infiltration in the optic nerve and spinal cord which was not present in Th1 EAE. Blockade of neutrophil elastase with Sivelestat had efficacy in Th17 EAE but not Th1 EAE.

Conclusions: The similarities between Th17 EAE and NMO indicate that this model represents several aspects of NMO. Neutrophils are critical in the pathologies of both Th17-EAE and NMO, and therefore blockade of neutrophil elastase is a promising target in treating NMO.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Animals
  • Cells, Cultured
  • Encephalomyelitis, Autoimmune, Experimental / drug therapy*
  • Encephalomyelitis, Autoimmune, Experimental / immunology
  • Encephalomyelitis, Autoimmune, Experimental / pathology
  • Female
  • Glycine / analogs & derivatives*
  • Glycine / therapeutic use
  • Glycoproteins / immunology
  • Humans
  • Interferon-beta / pharmacology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Middle Aged
  • Myelin-Oligodendrocyte Glycoprotein
  • Neuromyelitis Optica / drug therapy*
  • Neuromyelitis Optica / immunology
  • Neuromyelitis Optica / pathology
  • Pancreatic Elastase / antagonists & inhibitors*
  • Peptide Fragments / immunology
  • Serine Proteinase Inhibitors / therapeutic use*
  • Sulfonamides / therapeutic use*
  • Th1 Cells / cytology
  • Th1 Cells / immunology
  • Th17 Cells / cytology
  • Th17 Cells / immunology
  • Young Adult

Substances

  • Glycoproteins
  • Myelin-Oligodendrocyte Glycoprotein
  • Peptide Fragments
  • Serine Proteinase Inhibitors
  • Sulfonamides
  • myelin oligodendrocyte glycoprotein (35-55)
  • Interferon-beta
  • sivelestat
  • Pancreatic Elastase
  • Glycine